U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C43H58N4O12
Molecular Weight 822.9402
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of RIFAMPIN

SMILES

CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(O)C(\C=N\N5CCN(C)CC5)=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C4C(O)=C3C

InChI

InChIKey=JQXXHWHPUNPDRT-WLSIYKJHSA-N
InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

HIDE SMILES / InChI

Molecular Formula C43H58N4O12
Molecular Weight 822.9402
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/rifadin-drug.htm http://www.wikidoc.org/index.php/Rifampin_(oral)

Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. It is FDA approved for the treatment of tuberculosis, meningococcal carrier state. Healthy subjects who received rifampin 600 mg once daily concomitantly with saquinavir 1000 mg/ritonavir 100 mg twice daily (ritonavir-boosted saquinavir) developed severe hepatocellular toxicity. Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. Common adverse reactions include heartburn, epigastric distress, anorexia, nausea, vomiting, jaundice, flatulence, cramps.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P0A8V2
Gene ID: 948488.0
Gene Symbol: rpoB
Target Organism: Escherichia coli (strain K12)
18.5 µM [Ki]
30.2 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RIFADIN

Approved Use

In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. Tuberculosis Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive. RIFADIN IV is indicated for the initial treatment and retreatment of tuberculosis when the drug cannot be taken by mouth. Meningococcal Carriers Rifampin is indicated for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. Rifampin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms. (See WARNINGS.) Rifampin should not be used indiscriminately, and therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. So that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high. To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1971
Curative
RIFADIN

Approved Use

In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. Tuberculosis Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive. RIFADIN IV is indicated for the initial treatment and retreatment of tuberculosis when the drug cannot be taken by mouth. Meningococcal Carriers Rifampin is indicated for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. Rifampin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms. (See WARNINGS.) Rifampin should not be used indiscriminately, and therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. So that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high. To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1971
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
21.6 mg/L
20 mg/kg 1 times / day steady-state, oral
dose: 20 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
25.1 mg/L
25 mg/kg 1 times / day steady-state, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
33.1 mg/L
30 mg/kg 1 times / day steady-state, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
35.2 mg/L
35 mg/kg 1 times / day steady-state, oral
dose: 35 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.4 mg/L
10 mg/kg 1 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.3 mg/L
10 mg/kg 1 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.3 mg/L
10 mg/kg 1 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
325 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAMPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
113 mg × h/L
20 mg/kg 1 times / day steady-state, oral
dose: 20 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
135 mg × h/L
25 mg/kg 1 times / day steady-state, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
190 mg × h/L
30 mg/kg 1 times / day steady-state, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
235 mg × h/L
35 mg/kg 1 times / day steady-state, oral
dose: 35 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
26.3 mg × h/L
10 mg/kg 1 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.3 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
25-DESACETYLRIFAMPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
16.3 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAMPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
60 g single, oral (total)
Overdose
Dose: 60 g
Route: oral
Route: single
Dose: 60 g
Sources:
unknown, 26 years
n = 1
Health Status: unknown
Age Group: 26 years
Sex: M
Population Size: 1
Sources:
Other AEs: Pruritus...
Other AEs:
Pruritus (grade 5, 1 patient)
Sources:
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: adult
Population Size: 8
Sources:
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
unknown, adult
n = 18
Health Status: unknown
Age Group: adult
Sex: M
Population Size: 18
Sources:
AEs

AEs

AESignificanceDosePopulation
Pruritus grade 5, 1 patient
60 g single, oral (total)
Overdose
Dose: 60 g
Route: oral
Route: single
Dose: 60 g
Sources:
unknown, 26 years
n = 1
Health Status: unknown
Age Group: 26 years
Sex: M
Population Size: 1
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
yes [IC50 79.1 uM]
yes [Ki 18.5 uM]
yes [Ki 30.2 uM]
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: induced levels of CYP1C19 apoprotein to 330% of control; coadministration with simvastatin: decrease exposure of simvastatin; coadministration with irinotecan: decrease irinotecan and active metabolite exposure; rifampicin reduced AUC of repaglinide by 57%;
Page: 12.0
yes
yes (co-administration study)
Comment: Coadministration of ertugliflozin with rifampin decreased ertugliflozin AUC0-∞ and Cmax by 39% and 15%, respectively
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[New aspects of tuberculosis therapy].
1975 Feb 22
A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis. The results at 1 year. A cooperative tuberculosis chemotherapy study in Poland.
1975 Mar
[Side effects of rifampicin in the treatment of chronic pulmonary tuberculosis by the intermittent method].
1975 Mar 31
Acute renal failure after rifampicin: a case report and survey of the literature.
1976
Acute renal failure and hepatitis induced by intermittent rifampicin therapy.
1999 Aug
Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999.
2000 Apr
Antimycobacterial activities of novel levofloxacin analogues.
2000 Aug
A new class of antituberculosis agents.
2000 Aug 24
Renal allograft dysfunction associated with rifampin-tacrolimus interaction.
2000 Jan
[Isoniazid-induced hepatic failure. Report of a case].
2000 Jan-Mar
Mycobacterium tuberculosis infection in pediatric liver transplant recipients.
2000 Jul
Minimal change nephrotic syndrome associated with rifampicin treatment.
2000 Jul
Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction.
2000 Jul
CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers.
2000 Nov
Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex.
2000 Oct
Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.
2000 Oct
[Acute renal failure associated with rifampicin].
2000 Sep
Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors.
2000 Sep
Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.
2000 Sep
Hepatic failure and encephalopathy attributed to an interaction between acetaminophen and rifampicin.
2001 Apr
Bullous necrotizing fixed drug eruption with hepatitis due to rifampicin.
2001 Apr-Jun
Drug-induced acute interstitial nephritis.
2001 Aug
Sources of variation in studies of the early bactericidal activity of antituberculosis drugs.
2001 Feb
Continuous rifampicin administration inducing acute renal failure.
2001 Jan
Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
2001 Jan
[Acute kidney failure induced by rifampicin].
2001 Jan-Feb
[Clinico-pathological features and possible pathogenesis of rifampicin-induced acute renal failure].
2001 Jun
Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.
2001 Jun
Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines.
2001 Mar
CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit.
2001 May
[Acute renal insufficiency and interstitial nephritis caused by rifampicin. A comment on this subject].
2001 May-Jun
Antimycobacterial plant terpenoids.
2001 Nov
Acute renal failure complicating rifampicin therapy.
2001 Sep
The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds.
2002
Bactericidal activities of commonly used antiseptics against multidrug-resistant mycobacterium tuberculosis.
2002
Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis.
2002 Aug
Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis.
2002 Jan
[Specific features of acute renal failure in patients treated with rifampicin].
2002 Jan-Mar
Diffuse glomerulonephritis associated with rifampicin treatment for tuberculosis.
2002 Jun
Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR.
2002 May
3-[4'-bromo-(1,1'-biphenyl)-4-yl]-N, N-dimethyl-3-(2-thienyl)-2-propen-1-amine: synthesis, cytotoxicity, and leishmanicidal, trypanocidal and antimycobacterial activities.
2002 Nov
Acute renal failure due to rifampicin: a study of 25 patients.
2002 Oct
A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system.
2002 Oct
Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR).
2002 Oct 15
Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid.
2002 Oct 15
Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor.
2003 Apr
Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
2003 Apr
Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs.
2003 Jan
Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes.
2003 May
Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products.
2003 May
Patents

Sample Use Guides

Tuberculosis: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral or intravenous. It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water. Meningococcal Carriers: it is recommended that 600 mg rifampin be administered twice daily for two days.
Route of Administration: Other
By the absolute concentration method, the MIC50 and MIC90 of rifampicin were 0.5-1 mg/L
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:49:50 GMT 2023
Edited
by admin
on Sat Dec 16 15:49:50 GMT 2023
Record UNII
VJT6J7R4TR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIFAMPIN
HSDB   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
RIFALDAZINE
Common Name English
RIFAMPICIN [JAN]
Common Name English
BA-41166/E
Code English
RIMACTAN
Brand Name English
RIFATER COMPONENT RIFAMPIN
Common Name English
RIFAMPIN COMPONENT OF RIFATER
Common Name English
NSC-113926
Code English
RIFAMPICIN
EP   INN   MART.   WHO-DD   WHO-IP  
INN  
Official Name English
BA-41166E
Code English
RIMACTANE
Brand Name English
RIFAMPICIN [EP IMPURITY]
Common Name English
RIFADINE
Brand Name English
NIH-10782
Code English
RIFAMYCIN AMP
Common Name English
3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN
Systematic Name English
RIFA
Brand Name English
RIFAMPICIN [IARC]
Common Name English
RIFAMPIN COMPONENT OF RIFAMATE
Common Name English
RIFAMPIN [MI]
Common Name English
RIFAMPICINUM [WHO-IP LATIN]
Common Name English
L-5103 LEPETIT
Code English
RIFAPRODIN
Brand Name English
RIFAMYCIN, 3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)-
Common Name English
RIFAMPICIN [MART.]
Common Name English
BA 41166/E
Code English
RIFOLDIN
Brand Name English
RIFAMPICIN [WHO-IP]
Common Name English
RIFAPIAM
Brand Name English
RIFAMPIN [USAN]
Common Name English
RIFAMYCIN AMP [MI]
Common Name English
L-5103
Code English
rifampicin [INN]
Common Name English
L-5103-LEPETIT
Code English
RIFAMATE COMPONENT RIFAMPIN
Common Name English
RIFAMPIN [ORANGE BOOK]
Common Name English
R/AMP
Common Name English
5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate
Systematic Name English
ABRIFAM
Brand Name English
Rifampicin [WHO-DD]
Common Name English
EREMFAT
Brand Name English
RIFADIN
Brand Name English
RIFAMPIN [USP MONOGRAPH]
Common Name English
RIFAMPICIN [EP MONOGRAPH]
Common Name English
RIFAMPIN [HSDB]
Common Name English
RIFALDIN
Brand Name English
RIFAMPIN [VANDF]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 6585
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ETH/ISO/PYR/RIF)
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
NDF-RT N0000175500
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ISO/RIF)
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ISO/PYR/RIF)
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
FDA ORPHAN DRUG 7685
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.3
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
NDF-RT N0000007911
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
NDF-RT N0000007911
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-VATC QJ04AM05
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ATC J04AB02
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ATC J04AM07
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ATC J04AM02
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ATC J04AM05
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
NCI_THESAURUS C280
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
FDA ORPHAN DRUG 928022
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-VATC QJ04AB02
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
NDF-RT N0000007911
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-VATC QJ04AM02
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ATC J04AM06
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ETH/ISO/RIF)
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-VATC QJ04AM06
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
NDF-RT N0000007911
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
NCI_THESAURUS C25995
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
WHO-VATC QJ54AB02
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
LIVERTOX NBK548314
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
Code System Code Type Description
CHEBI
28077
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
CHEBI
71365
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
ChEMBL
CHEMBL374478
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
WIKIPEDIA
RIFAMPICIN
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
RIFAMPIN
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY Description: A brick red to red-brown, crystalline powder. Solubility: Very slightly to slightly soluble in water; soluble in methanol R; slightly soluble in acetone R, ethanol (~750 g/l) TS, and ether R. Category: Antileprosy drug; antituberculosis drug. Storage: Rifampicin should be kept in a tightly closed container or in an atmosphere of nitrogen, protected from light. Additional information: Rifampicin exhibits polymorphism. Definition: Rifampicin contains not less than 97.0% and not more than 102.0% of C43H58N4O12, calculated with reference to the dried substance.
SMS_ID
100000080561
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
DAILYMED
VJT6J7R4TR
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID6021244
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
RXCUI
9384
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY RxNorm
INN
2323
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
HSDB
3181
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
PUBCHEM
135398735
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
LACTMED
Rifampin
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
RS_ITEM_NUM
1604009
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
CAS
845504-52-1
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
ALTERNATIVE
MESH
D012293
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
IUPHAR
2765
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
ECHA (EC/EINECS)
236-312-0
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
NCI_THESAURUS
C811
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
EVMPD
SUB10309MIG
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
MERCK INDEX
m9611
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY Merck Index
DRUG CENTRAL
2377
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
DRUG BANK
DB01045
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
CAS
13292-46-1
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
NSC
113926
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
FDA UNII
VJT6J7R4TR
Created by admin on Sat Dec 16 15:49:54 GMT 2023 , Edited by admin on Sat Dec 16 15:49:54 GMT 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INDUCER
POTENT
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
POTENT
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INDUCER
TARGET -> INHIBITOR
TRANSPORTER -> INDUCER
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
SUBSTRATE USED: Bromsulphthalein (BSP)
TRANSPORTER -> INHIBITOR
CAN BE USED FOR IN-VIVO STUDIES OF TRANSPORTER
IN-VIVO
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Duration of Action PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: N. MENINGIDITIS

Biological Half-life PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC POPULATION: END-STAGE RENAL DISEASE

Tmax PHARMACOKINETIC POPULATION: PEDIATRICS

ROUTE OF ADMINISTRATION: ORAL

Cmax PHARMACOKINETIC POPULATION: PEDIATRICS

ROUTE OF ADMINISTRATION: ORAL

Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

POPULATION: PEDIATRICS

Biological Half-life PHARMACOKINETIC POPULATION: HEPATIC IMPAIRMENT

Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION: IV

POPULATION: PEDIATRICS

Cmax PHARMACOKINETIC POPULATION: PEDIATRICS

ROUTE OF ADMINISTRATION: IV

MIC BIOLOGICAL PATHOGEN: N. MENINGIDITIS

SUSCEPTIBILITY: SUSCEPTIBLE

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

MIC BIOLOGICAL PATHOGEN: N. MENINGIDITIS

SUSCEPTIBILITY: INTERMEDIATE